S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)

Adicet Bio Stock Price, News & Analysis (NASDAQ:ACET)

$1.38
+0.01 (+0.73%)
(As of 12/8/2023 ET)
Compare
Today's Range
$1.27
$1.41
50-Day Range
$1.11
$1.65
52-Week Range
$1.10
$19.84
Volume
302,863 shs
Average Volume
570,167 shs
Market Capitalization
$59.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.50

Adicet Bio MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
1,023.2% Upside
$15.50 Price Target
Short Interest
Bearish
9.98% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$15,125 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.90) to ($2.11) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

427th out of 954 stocks

Pharmaceutical Preparations Industry

140th out of 362 stocks


ACET stock logo

About Adicet Bio Stock (NASDAQ:ACET)

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and chimeric adaptors to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also develops ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors; and ADI-925, a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands. Adicet Bio, Inc. is based in Boston, Massachusetts.

ACET Stock Price History

ACET Stock News Headlines

Adicet Bio Inc Ordinary Shares
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Adicet Bio GAAP EPS of -$1.16
Adicet Bio, Inc Q3 Loss increases, misses estimates
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Will Adicet Bio (NASDAQ:ACET) Spend Its Cash Wisely?
Adicet Bio, Inc Q2 Loss increases, misses estimates
Massive Insider Trade At Adicet Bio
See More Headlines
Receive ACET Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adicet Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2023
Today
12/08/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/20/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Trading Companies & Distributors
Sector
Medical
Current Symbol
NASDAQ:ACET
CUSIP
00444610
CIK
2034
Fax
N/A
Employees
132
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.50
High Stock Price Target
$27.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+1,023.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Net Income
$-69,790,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$24.99 million
Book Value
$6.82 per share

Miscellaneous

Free Float
30,431,000
Market Cap
$59.57 million
Optionable
Optionable
Beta
1.86
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Chen Schor BAMr. Chen Schor BA (Age 51)
    CPA, M.B.A., CEO, President & Director
    Comp: $899.58k
  • Dr. Aya Jakobovits Ph.D. (Age 68)
    Founder & Independent Director
    Comp: $40k
  • Dr. Blake Aftab Ph.D. (Age 42)
    Senior VP & Chief Scientific Officer
    Comp: $675.04k
  • Dr. Francesco Galimi M.D. (Age 55)
    Ph.D., Chief Medical Officer & Senior VP
    Comp: $680.37k
  • Mr. Brian Nicholas Harvey (Age 62)
    Chief Financial Officer
    Comp: $596.79k
  • Dr. Donald Healey Ph.D. (Age 61)
    Chief Technology Officer
  • Ms. Amy Locke
    Head of Human Resources
  • Dr. Nancy L. Boman M.D.
    Ph.D., Senior VP & Chief Regulatory Officer














ACET Stock Analysis - Frequently Asked Questions

Should I buy or sell Adicet Bio stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adicet Bio in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ACET shares.
View ACET analyst ratings
or view top-rated stocks.

What is Adicet Bio's stock price target for 2024?

7 brokers have issued twelve-month price objectives for Adicet Bio's shares. Their ACET share price targets range from $5.00 to $27.00. On average, they predict the company's stock price to reach $15.50 in the next twelve months. This suggests a possible upside of 1,023.2% from the stock's current price.
View analysts price targets for ACET
or view top-rated stocks among Wall Street analysts.

How have ACET shares performed in 2023?

Adicet Bio's stock was trading at $8.94 at the beginning of 2023. Since then, ACET shares have decreased by 84.6% and is now trading at $1.38.
View the best growth stocks for 2023 here
.

Are investors shorting Adicet Bio?

Adicet Bio saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 3,030,000 shares, an increase of 6.7% from the October 31st total of 2,840,000 shares. Based on an average daily volume of 392,400 shares, the short-interest ratio is currently 7.7 days. Currently, 10.0% of the shares of the company are short sold.
View Adicet Bio's Short Interest
.

When is Adicet Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024.
View our ACET earnings forecast
.

How were Adicet Bio's earnings last quarter?

Adicet Bio, Inc. (NASDAQ:ACET) announced its earnings results on Wednesday, November, 8th. The company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.02.

Is Adicet Bio a good dividend stock?

Adicet Bio (NASDAQ:ACET) pays an annual dividend of $0.04 per share and currently has a dividend yield of 0.00%.
Read our dividend analysis for ACET.

What other stocks do shareholders of Adicet Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adicet Bio investors own include FluoroPharma Medical (FPMI), Aurora Cannabis (ACB), Twitter (TWTR), QUALCOMM (QCOM), Extreme Networks (EXTR), General Electric (GE), Altria Group (MO), Sirius XM (SIRI) and Adobe (ADBE).

Who are Adicet Bio's major shareholders?

Adicet Bio's stock is owned by many different institutional and retail investors. Top institutional shareholders include Cowen AND Company LLC (6.30%), Acadian Asset Management LLC (1.21%), Jacobs Levy Equity Management Inc. (0.77%), Northern Trust Corp (0.53%), Decheng Capital Management III Cayman LLC (0.46%) and GSA Capital Partners LLP (0.33%). Insiders that own company stock include Andrew Sinclair, Aya Jakobovits, Blake Aftab, Carl L Gordon, Chen Schor, Don Healey, Francesco Galimi, Jay P Elliott and Steve Dubin.
View institutional ownership trends
.

How do I buy shares of Adicet Bio?

Shares of ACET stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ACET) was last updated on 12/8/2023 by MarketBeat.com Staff

My Account -